Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors

Erin B. Bailey, Joseph Merriman, Benjamin Maughan, Austin Poole, Srinivas K. Tantravahi, Archana M. Agarwal, Julia A. Batten, Shiven B. Patel, Sumanta K. Pal, David D. Stenehjem, Neeraj Agarwal

Research output: Contribution to journalArticle

Abstract

Purpose: Hand-foot syndrome is a common dose limiting toxicity of vascular endothelial growth factor receptor tyrosine kinase inhibitors used for treatment of patients with metastatic renal cell carcinoma. The effect of treatment dose reductions, in the context of hand-foot syndrome, on survival outcomes is reported. Methods: This was a retrospective case series of patients receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors from 1 January 2004 to 31 October 2013. The main outcomes were progression-free and overall survival in these patients experiencing hand-foot syndrome and undergoing treatment dose reductions. Univariate and multivariate analyses were conducted utilizing Kaplan-Meier method and COX Proportional Hazard model with landmark analyses at 2 months. Results: Of the 120 patients evaluated, treatment dose reductions for any reason were required in 68 (56.7%) patients. The most common reasons for treatment dose reductions were mucositis, hand-foot syndrome, and fatigue. The median progression-free survival and overall survival were significantly longer in patients with hand-foot syndrome with or without treatment dose reductions as compared to those without hand-foot syndrome. Conclusions: An improvement in survival outcomes was observed in metastatic renal cell carcinoma patients with treatment-associated hand-foot syndrome despite treatment dose reductions. These data need validation in a larger cohort to confirm the hypothesis that treatment dose reductions in the setting of hand-foot syndrome do not negatively impatient survival.

Original languageEnglish (US)
Pages (from-to)190-197
Number of pages8
JournalJournal of Oncology Pharmacy Practice
Volume24
Issue number3
DOIs
StatePublished - Apr 1 2018

    Fingerprint

Keywords

  • Hand-foot syndrome
  • VEGFr-TKI
  • metastatic renal cell carcinoma
  • survival

Cite this